Dr. Mohammad Qasim Khan, MBBS, MS, FRCPC, is an Assistant Professor of Medicine in the Division of Gastroenterology at Western University in London, Canada, with cross-appointments in Epidemiology and Biostatistics and as an Associate Scientist at the London Health Sciences Research Institute, as well as the Institute for Clinical Evaluative Sciences. He is an academic transplant hepatologist and clinician-researcher whose work focuses on improving outcomes in patients with steatotic liver disease, particularly in the context of liver transplantation.

Dr. Khan completed his medical training at King Edward Medical University, followed by residency and fellowship training in Internal Medicine and Gastroenterology at the University of Chicago. He subsequently pursued advanced fellowship training in Transplant Hepatology at the Mayo Clinic. He also holds an Executive Master’s degree in Epidemiology from Columbia University.

His research program centers on cardiometabolic optimization in patients with liver disease, with a focus on metabolic dysfunction–associated steatotic liver disease (MASLD) and liver transplant recipients. He leads innovative work in risk stratification, non-invasive diagnostics, and multidisciplinary interventions to improve peri- and post-transplant outcomes. He is the founder and director of Canada’s first multidisciplinary MASLD clinic (COMET Clinic) and is actively involved in developing novel elastography and artificial intelligence–driven approaches to liver disease management.

Dr. Khan is an active member of multiple international liver societies (AASLD, CASL, ILTS) and serves on several steering committees, including the ILTS Vanguard Committee. He has authored numerous peer-reviewed publications and is a sought-after speaker on liver transplantation, MASLD, and cardiometabolic health.